Day: June 3, 2024

Viridien A French société anonymewith a share capital of € 7,136,762Registered office: 27 avenue Carnot, 91300 Massy, FranceEvry Trade and Companies Register 969 202 241 Information on the total number of voting rights and shares Pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial markets authority (AMF- Autorité des Marchés Financiers)Date of the information Total number of issued shares Number of actual voting rights* Number of theoretical voting rights**May 31, 2024 713,676,258 715,925,525 715,950,521* All of the Company shares have the same voting rights, except for treasury shares which do not have voting rights and registered shares held for more than two years, which have double voting rights.** Pursuant to Article 223-11 of the General Regulation...

LONDON, June 03, 2024 (GLOBE NEWSWIRE) — WTW (NASDAQ: WTW), a leading global advisory, broking and solutions company, today unveiled ground-breaking technology capable of quantifying the financial impact of climate change with an unprecedented level of precision. Climate Quantified™ offers ‘anywhere, anytime’ access, transparently assessing how and when physical and transition risks impact a company’s operations and assets, through to their revenue and enterprise value. The Software as a Service (SaaS) online tool also evaluates the impact of climate risks on an organisation’s customers and supply chain partners, as a necessary component of understanding financial impact of climate risks. Assessing where a business creates value and their exposure to a changing operational landscape from climate risks brings a new level...

DÜSSELDORF, Germany, June 03, 2024 (GLOBE NEWSWIRE) — FTI Consulting Inc. (NYSE: FCN) today announced the continued expansion of its business transformation capabilities in Europe with the addition of chemicals industry expert Stefan Van Thienen, who joins the firm as a Senior Managing Director in the Corporate Finance & Restructuring segment. His arrival follows the recent launch of the firm’s Business Transformation practice in Belgium with the addition of Jean-Michel Mollo. Mr. Van Thienen specialises in operational management and business optimisation within the chemicals sector, particularly in the areas of sustainability and digital transformation. In his role at FTI Consulting, he will help expand the firm’s chemicals capabilities within its business transformation offering across Europe to provide clients with a broad...

PRESS RELEASEParis, 3 June 2024 Agreement reached with the government on funding of private hospitals After two months of mass mobilisation and intense discussions with the government, a compromise was reached on 24 May 2024 between the government and the Federation of private clinics and hospitals, set out in a letter of commitment from the delegate Ministry of Health. The Government’s commitment includes, first and foremost, the principle of equal treatment between the private and public hospital sectors, which is a major step forward for all private hospitals, of which Ramsay Santé is the leading player. It also specifies that a multi-year agreement on tariffs for the period 2025-2027 should be finalised by mid-July 2024, as well as increased access for the private sector to regional funding (FIR and MIGAC) from which it was almost...

London (UK), June 3, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, today announces it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) protecting a group of molecules and their ability to trigger an immune response across a wide range of cancers by detaching the Hexokinase-2 (HK2) enzyme from the mitochondrial VDAC pores. The molecules are the crucial compounds in Vidac’s two drug candidates, VDA-1102 and VDA-1275. “This U.S. patent goes to the heart of Vidac’s efforts to develop an entirely new class of cancer drugs for patients. Our molecules have the ability to dislodge the HK2 enzyme from the mitochondrial VDAC pores, which reverses...

Patient screening and enrollment initiated for the Phase II part of the international randomized Phase I/II trial with an overall sample size of approximately 80 patients. Last patient enrollment for Phase II part expected in Q4 2025. Strasbourg, France, June 3, 2024, 7:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer today announces that the first patient has been enrolled in the Phase II part of the randomized Phase I/II clinical trial of the individualized therapeutic cancer vaccine, TG4050, in the adjuvant treatment of head and neck cancer. Patient screening and enrollment are active, with the aim of enrolling 80 patients internationally in the overall Phase I/II trial. TG4050 is based on Transgene’s myvac® viral vector platform and NEC’s...

   Ipsen initiates a share buy-back program to cover its free employee share-allocation plan and employee share plan PARIS, FRANCE, 3 June 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) has appointed an investment-services provider to purchase an aggregate number of Ipsen S.A. shares up to 400,000, or about 0.47% of the share capital, over a maximum period of six months. The shares purchased under this agreement will be allocated mainly to cover Ipsen’s free employee share-allocation plan and its new employee share-ownership plan. This program is made pursuant to the authorization granted by the Company’s Annual General Meeting, held on 28 May 2024. ENDS About Ipsen We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience....